Vertex announces advancements of Suzetrigine in acute and neuropathic pain

Breakthrough Therapy designation for pain associated with DPN granted by FDA

AbbVie announces late-breaking data at AAN supporting efficacy of Atogepant for preventive treatment of migraine

Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024

Novartis tender offer for MorphoSys commences

The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months

Briefs: Sun Pharma and Kimia Biosciences

Sun Pharma's Dadra facility receives OAI status from US FDA

Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.

SPARC announces results from planned interim analysis of PROSEEK Study

Briefs: Alkem Laboratories and Zydus Lifesciences

USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant

Asahi Songwon Colors acquires remaining 22% stake in Atlas Life Sciences

Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%

Caplin Group commences operations of Rs. 150 crore oncology facility

The facility will manufacture tablets, capsules, and injections for the oncology segment